On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...
Zacks.com on MSN19h
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-TermTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
Zacks.com on MSN1d
BioMarin (BMRN) Upgraded to Buy: Here's WhyBioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioMarin Pharmaceutical ( BMRN -4.44%), a leader in treatments for rare genetic disorders, released its Q3 2024 earnings on ...
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Joseph Schwartz has ...
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...
In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...
Biomarin Pharmaceutical Inc (BMRN) Stock Settles at $69.91: What’s Contributing to This Price Point?
On Tuesday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $69.91 which represents a decrease of $-0.22 or -0.31% from the prior close of $70.13. The stock opened at $69.78 ...
Thank you for standing by. My name is Bary, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceuticals third-quarter 2024 conference ...
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback